1364 Discovery of NXA01, a novel CD24 antibody with tumor selectivity and potent anti-tumor activity

Jun‐Li Liu, P. Yuan, Lei Ying, Guanghua Lv, Yang Xie, Fan Liu, Taylor B. GuoRegular 2023 · DOI

TL;DR

Researchers have developed NXA01, a novel antibody that targets CD24, a "don't-eat-me" signal used by cancer cells to evade the immune system. Unlike previous attempts, NXA01 is highly selective, specifically targeting the "stripped-down" (hypoglycosylated) version of CD24 found on tumors while sparing healthy cells, potentially offering a safer and more potent immunotherapy.

What Problem Does This Paper Address?

The immune system is naturally equipped to clear abnormal cells, but cancers often deploy "molecular camouflage" to stay hidden. One such shield is CD24, a protein overexpressed in various cancers (breast, ovarian, lymphoma). CD24 binds to Siglec-10 on macrophages, sending a "don't-eat-me" signal that prevents the immune system from engulfing the tumor.

While targeting CD24 is a promising strategy, there is a major catch: CD24 is also present on some healthy cells, such as B cells and granulocytes. A non-selective antibody would attack these healthy cells, leading to "on-target, off-tumor" toxicity. The challenge addressed here is creating an antibody that can distinguish between "cancerous" CD24 and "healthy" CD24.

Methods

The team at NeoX Biotech used a multi-pronged approach to discover and refine NXA01:

  • Differential Immunization: They immunized mice using human CD24 purified from two different sources: E. coli (which produces non-glycosylated proteins) and 293T mammalian cells (which produce fully glycosylated proteins). This allowed them to screen for antibodies that recognize specific structural states of the protein.
  • Precision Screening: They used Surface Plasmon Resonance (SPR) to measure binding affinity and Flow Cytometry (FACS) to ensure the antibody bound to tumor cells but ignored normal human blood cells.
  • Protein Engineering: The lead candidate was humanized in silico (using computer modeling) and further optimized through affinity maturation via saturation mutation to ensure it binds its target as tightly as possible.
  • Mechanistic Assays: They performed co-culture studies to measure ADCC (Antibody-Dependent Cellular Cytotoxicity) and ADCP (Antibody-Dependent Cellular Phagocytosis)—essentially testing if the antibody successfully "tags" cancer cells for destruction by Natural Killer cells and macrophages.

Datasets

The researchers evaluated NXA01 across several biological models:

  • Cancer Cell Lines: NALM6 (B-cell precursor leukemia) and MDA-MB-468 (triple-negative breast cancer).
  • Normal Primary Cells: Human granulocytes and B cells (used as a "negative control" to test selectivity).
  • In Vivo Models: MC38 cells (mouse colon cancer) engineered to express human CD24, along with NALM6 and MDA-MB-468 xenografts in mice.

Key Insights and Ideas

  • The Glycan "Tell": The most significant finding is that NXA01’s selectivity is driven by the glycosylation state of CD24. Cancer cells often have "messy" or incomplete sugar coatings (hypoglycosylation). NXA01 preferentially binds to these "naked" versions of the protein. When the researchers enzymatically stripped the sugars off healthy cells, NXA01 suddenly started binding to them, proving that the sugar coating is what normally protects healthy cells from this drug.
  • Dual-Action Weaponry: NXA01 doesn't just block the "don't-eat-me" signal (the checkpoint blockade). It also actively recruits immune cells to kill the tumor via ADCC and ADCP. This "one-two punch" makes it more effective than a simple blocking agent.
  • Synergy with Existing Drugs: The study found that NXA01 enhanced the phagocytic activity of tafasitamab (an anti-CD19 antibody), suggesting it could be a powerful partner in combination therapies.

Key Results

  • High Affinity: NXA01 binds to CD24 with a very strong affinity of 1.5 nM.
  • Potent Blockade: It successfully blocked the CD24-Siglec10 interaction with an EC50 of 8 nM.
  • Tumor Selectivity: In mixed cultures of tumor and normal cells, NXA01 mediated the killing of cancer cells (EC50 < 10 nM) while leaving normal B cells untouched.
  • In Vivo Efficacy: In mouse models, NXA01 treatment led to dramatic tumor growth inhibition:
  • 104% inhibition in MC38-hCD24 models (indicating tumor regression).
  • 105% inhibition in NALM6 models.
  • 51% inhibition in MDA-MB-468 breast cancer models.

Limitations and Future Work

While the results are highly promising, the paper notes a few areas for further development:

  • Variable Efficacy: The inhibition in the breast cancer model (51%) was notably lower than in the leukemia/lymphoma models (100%+). This suggests that tumor microenvironments or varying CD24 glycan profiles in solid tumors may impact performance.
  • Clinical Translation: As this is a poster abstract, the data is pre-clinical. The authors state that IND-enabling studies (the final safety and manufacturing tests required before human trials) are currently ongoing. The true test of its "best-in-class" potential will be its safety profile in human patients.

Summary updated

Abstract

<h3>Background</h3> CD24 is a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein overexpressed on multiple types of cancers including lymphoma, breast cancer, ovarian cancer, where it reportedly regulates cell migration, invasion, proliferation and immune escape.<sup>1</sup> Apart from being viewed as a tumor-associated antigen (TAA), CD24 was recently found to suppress tumor phagocytosis by delivering a ‘don’t-eat-me’ signal via binding to Siglec-10 expressed on tumor-associated macrophages.<sup>2</sup> We hypothesize that selective tumor targeting of the CD24-Siglec-10 pathway by anti-CD24 mAb may represent a novel therapeutic approach to enhance anti-cancer immunity while avoiding potential on-target off-tumor toxicity. <h3>Methods</h3> We immunized mice with the extracellular portion of human CD24 purified from both the <i>E. coli</i> and 293T expression systems and screened for hCD24-binding hybridomas by ELISA. We evaluated the affinity of binders by SPR and selective tumor cell binding over normal cells by FACS. We profiled lead antibodies in ADCC and ADCP co-culture studies and in <i>in vivo</i> tumor cell efficacy models. We humanized the best clone <i>in silico</i> and affinity matured it by saturation mutation. We determined the epitope of the lead candidate (NXA01) by overlapping peptide blocking and co-crystallography studies. <h3>Results</h3> With an affinity of 1.5 nM as determined by SPR, NXA01 bound to hCD24 on tumor cells such as NALM6 and MDA-MB-468 but not to normal human granulocytes or B cells. This tumor selectivity was related to preferential binding of NXA01 to aglycosylated or hypogylcosylated hCD24 as enzymatic deglycosylation of normal cells restored binding. NXA01 blocked hCD24-Siglec10 interaction with an EC50 of 8 nM and as a result enhanced ADCP activity of tafasitamab (anti-CD19). NXA01 could also mediate direct killing of NALM6 and MDA-MB-468 cells through both ADCC and ADCP at EC50s of &lt;10 nM, but it spared normal B cells in a tumor/normal mixed cell culture, further indicating tumor selectivity. Finally, NXA01 treatment significantly inhibited the growth of MC38-hCD24, NALM6 and MDA-MB-468 tumor cells <i>in vivo</i> with maximal inhibition of 104%, 105% and 51%, respectively. <h3>Conclusions</h3> NXA01 is a potential best-in-class CD24 blocking antibody that exhibits selective tumor binding and strong anti-tumor activity <i>in vitro</i> and <i>in vivo</i>. The dual mechanism of ADCC and macrophage checkpoint blockade makes NXA01 a good candidate for monotherapy as well as a combination partner with other TAA or immune-oncological drugs. IND-enabling studies are ongoing for NXA01. <h3>References</h3> Altevogt P, Sammar M, Hüser L, Kristiansen G. Novel insights into the function of CD24: A driving force in cancer. <i>Int. J. Cancer</i>. 2021;<b>148</b>:546–559 Barkal AA, Brewer RE, Markovic M, <i>et al</i>. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. <i>Nature</i>. 2019;<b>572</b>:392–396.
BibTeX
@inproceedings{liu2023discovery,
  author = {Jun‐Li Liu and P. Yuan and Lei Ying and Guanghua Lv and Yang Xie and Fan Liu and Taylor B. Guo},
  title = {{1364 Discovery of NXA01, a novel CD24 antibody with tumor selectivity and potent anti-tumor activity}},
  booktitle = {Regular},
  year = {2023},
  doi = {10.1136/jitc-2023-sitc2023.1364},
}
Figure